Public Health, Disease Prevention & WellnessAREXVY Recommended for Adults 50-59 at Increased RSV RiskBusiness WireApril 17, 2025April 18, 2025 by Business WireApril 17, 2025April 18, 202509 GSK plc (LSE/NYSE: GSK) is pleased that the Advisory Committee on Immunization Practices (ACIP) voted in favor of recommending the use of RSV vaccinesincluding GSK’sAREXVY(Respiratory...
